Oculis is a helvetico-Icelandic biopharmaceutical company focused on creating innovative treatments for eye and neurological disorders. The firm is legally based in Zug with its operational headquarters in Lausanne. Its pipeline of ophthalmic therapies has attracted strong investor interest, reflected in two capital increases exceeding $100 million within a year. Management states that the newly secured funds will accelerate the clinical development of its drug candidates. The company positions itself as a leader in addressing unmet medical needs in ophthalmology through novel therapeutic approaches. Financially, Oculis has now raised at least $220 million across its last two rounds, underscoring sustained investor confidence. No revenue or user metrics were disclosed in the available article excerpt.

Total raised

$296M

Funding rounds

6

Latest round

Equity

Latest activity

Oct 2025